A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
• Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.
Locations
Other Locations
Republic of Korea
Andong Hospital
RECRUITING
Andong
Konkuk University medical center
NOT_YET_RECRUITING
Seoul
Contact Information
Primary
Shin-young Oh
syoh@boryung.co.kr
+82-2-708-8000
Time Frame
Start Date: 2024-09-30
Estimated Completion Date: 2027-03
Participants
Target number of participants: 10000
Related Therapeutic Areas
Sponsors
Leads: Boryung Pharmaceutical Co., Ltd